Albumin to help water pills work in cirrhosis with fluid buildup
Tests albumin against saline for fluid removal in people with cirrhosis and ascites.
Key facts
- Who runs it
- Anahita Rabiee MD MHS
- Where
- West Haven, United StatesSee the site
- Trial code
- Registry title
- Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 20 people, planned
- Started
- 28 Feb 2025
- Expected to end
- Mar 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Albumin infusion (25% albumin)
- Normal Saline (0.9% NaCl)
- Record updated
- 11 March 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adult outpatients with decompensated cirrhosis, past or current fluid in the belly (ascites), and ongoing leg swelling. It compares one dose of albumin with one dose of placebo.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Decompensated cirrhosis (advanced liver scarring causing problems) with past or current ascites. Leg swelling continues despite adjusting diuretic (water pill) tablets.
- Earlier treatment
- Must be taking oral diuretics adjusted over time. No change in oral diuretics in the past 7 days. No large fluid drainage from the belly (paracentesis) in the past 7 days. No albumin infusion in the previous 14 days. Other diuretics such as Hydrochlorothiazide are not allowed; amiloride or eplerenone instead of spironolactone, and Bumex/Torsemide instead of furosemide, are allowed.
- Biomarker or test result
- Serum albumin below 3.5 g/dL
Main reasons for not taking part
- Kidney function (GFR) below 30mL/min/1.73 m2
- Belly infection (spontaneous bacterial peritonitis) in the past month, or active bleeding from swollen veins (varices)
- Current confusion from liver disease (hepatic encephalopathy grade 2 or higher)
- Low blood pressure (mean below 65 mmHg or systolic below 90 mmHg), sodium below 125 mEq/L, or heart failure with EF below 50%
- Needing oxygen at baseline, or allergy to albumin products
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Outpatient patients with decompensated cirrhosis with past or current ascites and persistent lower extremity edema despite oral diuretic titration
- Serum albumin of < 3.5 g/dL
- Age >=18 years old
Who cannot take part
- previous diagnosis of overt heart failure (systolic EF < 50%)
- Active variceal bleeding
- Patients with GFR < 30mL/min/1.73 m2
- Albumin infusion within the previous 14 days (** patients can enter the study after 14 days)
- Severe hyponatremia (Sodium <125 mEq/L)
- Hypersensitivity to albumin preparations
- Changes in oral diuretic regimen in the past 7 days (**patients can enter the study after 7 days of the change)
- Large Volume paracentesis (LVP) in the past 7 days (**patients can enter the study after 7 days)
- Spontaneous Bacterial Peritonitis in the past month
- Current Hepatic encephalopathy (>= Grade 2 based on West Haven criteria)
- Co-administration of other diuretics such as Hydrochlorothiazide (amiloride or eplerenone in place of spironolactone, and Bumex/Torsemide in place of furosemide are acceptable)
- Hypotension (Mean Arterial Pressure <65 mmHg, Systolic Blood pressure <90 mmHg)
- Baseline oxygen requirement
Where in United States
- West Haven VA Medical CenterWest Haven, United StatesContact: Anahita Rabiee, MD, MHSTaking people
About the trial
What the trial wants to find out
A small, pilot proof-of-concept placebo-controlled trial to explore the effects of albumin on diuresis in patients with cirrhosis, ascites and lower extremity edema. We will additionally investigate albumin's effect on preventing neurohumoral activation, and acute kidney injury after diuresis.
The 2 groups in the trial
- Albumin firstExisting treatment, for comparison
Albumin for one dose, followed by at least 14 day washout period, before crossing over to the alternate arm to receive placebo for one dose.
- Placebo firstPlacebo, for comparison
Placebo for one dose, followed by at least 14 day washout period, before crossing over to the alternate arm to receive albumin for one dose.
Treatment: Albumin infusion (25% albumin) and Normal Saline (0.9% NaCl)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Albumin Assisted Diuresis in Patients with Cirrhosis Decompensated by Ascites and Peripheral Edema, a Proof-of-concept Double Blind Randomized Trial
- Plain-language title
- Albumin to help water pills work in cirrhosis with fluid buildupGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 11 March 2025